AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34020837
Drug: Continuous positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous positive pressure treatment for OSA
Trial: 34020837
Drug: Best treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best treatment of each disease separately and recognition and treatment of comorbidities
Trial: 32057716
Drug: Calorie restriction
RxNorm normalized name: Resurrection Lily Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calorie restriction (CR) - 70% of energy needs daily
Trial: 35130863
Drug: Group L
RxNorm normalized name: Blood group Lewis alpha-4-fucosyltransferase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group L (intraoperative warming set to 38 °C)
Trial: 34684312
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g of L-citrulline
Trial: 32408390
Drug: Tamsulosin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.4 mg once a day)
Trial: 32408390
Drug: Mirabegron (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron (50 mg once a day)
Trial: 35655485
Drug: Control (Conservative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Conservative Treatment)
Trial: 35799169
Drug: Rubus idaeus
RxNorm normalized name: RUBUS IDAEUS LEAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rubus idaeus leaf extract 400 mg
Trial: 35799169
Drug: Rubus idaeus
RxNorm normalized name: RUBUS IDAEUS LEAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rubus idaeus leaf extract 200 mg
Trial: 34133348
Drug: Edaravone (EDA)
DrugBank: Edaravone (DB12243)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Edaravone (EDA) administered intravenously 30 min before surgery
Trial: 32916151
Drug: High Fructose
RxNorm normalized name: High Fructose Corn Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Fructose Corn Syrup (HFCS) (25% of energy requirements)
Trial: 37270883
Drug: Intracoronary tirofiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary tirofiban (25 mcg/kg infused over 5 minutes followed by 0.15 mcg/kg/min for 12-18 hours)
Trial: 38821658
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no laser treatment)
Trial: 32314038
Drug: Obinutuzumab-chemotherapy
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab-chemotherapy
Trial: 33888067
Drug: Aripiprazole (1-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (1-15 mg/day)
Trial: 33484095
Drug: Boost articulation
RxNorm normalized name: BOOST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boost articulation therapy (BArT)
Trial: 33039958
Drug: Combined immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined immunotherapy (anti-PD-1 antibody) and antiangiogenic therapy
Trial: 32404342
Drug: Canakinumab (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab (4 mg/kg, maximum 300 mg subcutaneous every 4 weeks)
Trial: 39418460
Drug: Prolonged exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged exposure (PE) therapy
Trial: 33419674
Drug: Herbal medicine
RxNorm normalized name: Herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal medicine therapy (Jinhaoartemisia antipyretic granules and Huoxiangzhengqi oral liquids)
Trial: 34402024
Drug: Trans-resveratrol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trans-resveratrol (500 mg orally once daily for 52 weeks)
Trial: 32747036
Drug: Low-dose estradiol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose estradiol (0.5 mg) / dydrogesterone (2.5 mg)
Trial: 35647831
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise plus metformin (AEM)
Trial: 35647831
Drug: Metformin only
RxNorm normalized name: Metformin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin only (M)
Trial: 34213061
Drug: Isatuximab in
RxNorm normalized name: isatuximab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isatuximab in combination with pomalidomide and dexamethasone (IsaPd)
Trial: 34578808
Drug: Sil-Q1 (SQ;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sil-Q1 (SQ; silk peptide) 7.5 g for 8 weeks
Trial: 33764994
Drug: Insulin plus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin plus fatty acids (Intralipid plus heparin)
Trial: 33764994
Drug: Saline/heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline/heparin
Trial: 36346039
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: isotretinoin 0.5‐1 mg/kg/day for 24 weeks
Trial: 36346039
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: isotretinoin 0.25‐0.4 mg/kg/day for 24 weeks
Trial: 36346039
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: isotretinoin 0.5‐0.7 mg/kg/day for 1 week out of every 4 weeks for 24 weeks
Trial: 32613329
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (60 mg of elemental iron in combined iron–folic acid pills) from 12 weeks of gestation until delivery
Trial: 34433548
Drug: Selective laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective laser trabeculoplasty (SLT): approximately 100 shots, 3 ns, 400 µm spot size administered 360 degrees at the limbus using any gonioscopy lens, energy 0.3‐2.6 mJ.
Trial: 34748164
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of long-term antidepressant medication
Trial: 34748164
Drug: Long-term maintenance
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term maintenance antidepressants
Trial: 33504262
Drug: Topical EPO
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical EPO and standard-of-care (SOC)
Trial: 33504262
Drug: Topical EPO
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical EPO and SOC
Trial: 33504262
Drug: Topical EPO
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical EPO
Trial: 33744327
Drug: GDC-0214 15
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GDC-0214 15 mg QD
Trial: 33744327
Drug: GDC-0214 15
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GDC-0214 15 mg twice daily
Trial: 32140784
Drug: Eldecalcitol (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eldecalcitol (0.75 μg)
Trial: 32140784
Drug: Alfacalcidol (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol (1.0 μg)
Trial: 36075773
Drug: Remimazolam at
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam at doses of 0.25–0.33 mg kg−1 for patients aged <40
Trial: 36075773
Drug: Remimazolam at
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam at doses of 0.19–0.25 mg kg−1 for patients aged 40–60
Trial: 36075773
Drug: Remimazolam at
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam at doses of 0.14–0.19 mg kg−1 for patients aged 60–80
Trial: 33481053
Drug: injectable platelet-rich
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injectable platelet-rich fibrin (i-PRF) injected into the mucosa on the buccal and palatal aspects of the intervention sides, repeated one month later
Trial: 37275963
Drug: Ribociclib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib plus endocrine therapy (ET)
Trial: 33149768
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus endocrine therapy (ET)
Trial: 36378778
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (extended-release niacin and placebo)
Trial: 32798376
Drug: Diabetic patients
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetic patients (gender, age, treatment type)
Trial: 32798376
Drug: Gender, age,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gender, age, and treatment type
Trial: 32354652
Drug: Ectoin® Eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ectoin® Eye Spray (EES09)
Trial: 32354652
Drug: Tears Again®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tears Again® Eye Spray (TA)
Trial: 34756796
Drug: Standard hand
RxNorm normalized name: ALCOHOL 48 mL in 60 mL TOPICAL LIQUID [Silver Standard Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard hand therapy plus workplace-based educational intervention (Working Hands-ED) for 12 weeks
Trial: 34756796
Drug: Standard hand
RxNorm normalized name: ALCOHOL 48 mL in 60 mL TOPICAL LIQUID [Silver Standard Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard hand therapy for 12 weeks
Trial: 34996108
Drug: IV dex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV dex (1ug/kg) with propofol (1 mg/kg)
Trial: 34996108
Drug: IV propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV propofol (1 mg/kg)
Trial: 35367070
Drug: AS01B‐adjuvanted HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS01B‐adjuvanted HBV surface antigen vaccine
Trial: 32163508
Drug: Ibuprofen and
RxNorm normalized name: Ibuprofen and Famotidine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen and GS‐561937 (FPI) combination therapy started at 3 days post infection
Trial: 32163508
Drug: Ibuprofen and
RxNorm normalized name: Ibuprofen and Famotidine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen and GS‐561937 (FPI) combination therapy started at 5 days post infection
Trial: 32163508
Drug: Ibuprofen alone
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen alone started on day 3
Trial: 32163508
Drug: FPI with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPI with ibuprofen started on day 3
Trial: 35219277
Drug: Sarilumab 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab 400 mg
Trial: 33779203
Drug: WSWS2-L (long
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WSWS2-L (long version with 19 items)
Trial: 35670658
Drug: Hyperinsulinemic-hypoglycemic phase
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperinsulinemic-hypoglycemic phase (2.5 mmol/L) followed by recovery to hyperglycemia (20 mmol/L)
Trial: 35670658
Drug: Recovery phase
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recovery phase in hyperglycemia (20 mmol/L)
Trial: 35670658
Drug: Recovery phase
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recovery phase in euglycemia (5.0-8.0 mmol/L)
Trial: 36215226
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose vitamin D (800 IU/day)
Trial: 36215226
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose vitamin D (3200 IU/day)
Trial: 33727268
Drug: Standard maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard maintenance therapy
Trial: 35193803
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 0.5 g/L tranexamic acid (TXA)
Trial: 33421230
Drug: Oral sucrosomial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sucrosomial iron (SI) 28 mg daily for 3 months
Trial: 33964855
Drug: 10 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 µg vitamin D3/d
Trial: 33637605
Drug: D-allulose 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-allulose 7.5 g
Trial: 33637605
Drug: D-allulose 10
RxNorm normalized name: D & C YELLOW #10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-allulose 10 g
Trial: 32938620
Drug: Palbociclib 200
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib 200 mg daily for 2 weeks and 1 week off plus trastuzumab (cohort A)
Trial: 32938620
Drug: Palbociclib 200
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib 200 mg daily for 2 weeks and 1 week off plus trastuzumab (cohort B1)
Trial: 32938620
Drug: Palbociclib 200
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib 200 mg daily for 2 weeks and 1 week off plus trastuzumab (cohort B2)
Trial: 32938620
Drug: Palbociclib in
RxNorm normalized name: Product containing palbociclib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palbociclib in combination with trastuzumab
Trial: 34349503
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of regorafenib (40 mg)
Trial: 34349503
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of regorafenib (Stivarga®, 40 mg)
Trial: 34349503
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations of regorafenib (40 mg)
Trial: 33784411
Drug: Intranasal corticosteroids
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal corticosteroids (INCS) - triamcinolone acetonide (220 µg)
Trial: 32810089
Drug: Kangaroo mother
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kangaroo mother care therapy
Trial: 36417057
Drug: Rimegepant 75
RxNorm normalized name: rimegepant 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimegepant 75 mg EOD
Trial: 36417057
Drug: Rimegepant 75
RxNorm normalized name: rimegepant 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimegepant 75 mg EOD (after switching from placebo)
Trial: 32991399
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine + diet
Trial: 32347777
Drug: Trivalent inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent inactivated influenza vaccine (IIV3) administered intradermally or intramuscularly
Trial: 34871580
Drug: 1.62% transdermal
RxNorm normalized name: Androgel 1.62% Transdermal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.62% transdermal testosterone gel
Trial: 34871580
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo gel
Trial: 35543281
Drug: RSVpreF 60
RxNorm normalized name: RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSVpreF 60 µg with Al(OH)3
Trial: 35543281
Drug: RSVpreF 60
RxNorm normalized name: RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSVpreF 60 µg with CpG/Al(OH)3
Trial: 35543281
Drug: RSVpreF 120
RxNorm normalized name: RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSVpreF 120 µg with Al(OH)3
Trial: 35543281
Drug: RSVpreF 120
RxNorm normalized name: RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSVpreF 120 µg with CpG/Al(OH)3
Trial: 35543281
Drug: RSVpreF 240
RxNorm normalized name: RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSVpreF 240 µg with Al(OH)3
Trial: 35543281
Drug: RSVpreF 240
RxNorm normalized name: RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSVpreF 240 µg with CpG/Al(OH)3
Trial: 35543281
Drug: RSVpreF 240
RxNorm normalized name: RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSVpreF 240 µg unadjuvanted
Trial: 35543281
Drug: RSVpreF 240
RxNorm normalized name: RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSVpreF 240 µg with CpG/Al(OH)3 (month 0,2 cohort)
Trial: 35543281
Drug: High-dose seasonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose seasonal inactivated influenza vaccine (SIIV)
Trial: 35543281
Drug: RSVpreF formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSVpreF formulations
Trial: 33148479
Drug: Abemaciclib 150
RxNorm normalized name: abemaciclib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib 150 mg plus Tamoxifen 20 mg (A+T)
Trial: 33148479
Drug: Abemaciclib 200
RxNorm normalized name: abemaciclib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib 200 mg plus prophylactic loperamide (A-200)
Trial: 33148479
Drug: Abemaciclib 150
RxNorm normalized name: abemaciclib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib 150 mg every 12 hours (A-150)
Trial: 36219407
Drug: Paroxetine 40
RxNorm normalized name: PARoxetine 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 40 mg daily plus Oxycodone 10 mg
Trial: 36219407
Drug: Quetiapine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (100 mg to 400 mg) plus Oxycodone 10 mg
Trial: 36219407
Drug: Paroxetine 40
RxNorm normalized name: PARoxetine 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 40 mg daily
Trial: 36219407
Drug: Quetiapine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (100 mg to 400 mg)
Trial: 36219407
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus Oxycodone 10 mg
Trial: 33941921
Drug: Durvalumab in
RxNorm normalized name: durvalumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab in combination with FGFR inhibitors
Trial: 33941921
Drug: Durvalumab in
RxNorm normalized name: durvalumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab in combination with PARP inhibitors
Trial: 33941921
Drug: Durvalumab in
RxNorm normalized name: durvalumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab in combination with TORC1/2 inhibitors
Trial: 38430375
Drug: Durvalumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab monotherapy
Trial: 32469260
Drug: Beetroot extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot extract (600 mg in capsule)
Trial: 32612186
Drug: Placebo (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (600 mg starch in capsule)
Trial: 32173607
Drug: Nasal high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high flow (NHF) 30 L/min
Trial: 32173607
Drug: Nasal high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high flow (NHF) 60 L/min
Trial: 32912274
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg elacestrant QD (escalated to 400 mg after 14 days)
Trial: 32912274
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg elacestrant QD
Trial: 32912274
Drug: Elacestrant (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elacestrant (200 mg and 400 mg QD)
Trial: 34865095
Drug: Local oxygen‐ozone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local oxygen‐ozone therapy plus medical treatment
Trial: 35665526
Drug: Dialectical behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical behavior therapy for binge-eating disorder (DBT-BED)
Trial: 35665526
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT+)
Trial: 33068349
Drug: Routine anti-infection
RxNorm normalized name: gentian violet
DrugBank: Gentian violet cation (DB00406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine anti-infection and symptomatic and supportive treatment (Control Group)
Trial: 32740214
Drug: Fractionally ablative
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractionally ablative Er:YAG resurfacing, 3 treatments at monthly intervals
Trial: 35473348
Drug: Low dosage
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dosage of MKA plus lifestyle modifications